Riskpilot← Back to searchSign inGet full accessBERGEN ØRE-NESE-HALS AS
ASActiveOrg 919434007Christian Michelsens Gate 4, 5012 BergenMedical specialists activities · NACE 8622Est. 20177 employees
Revenue 2025
NOK 7,6M
-3% vs 2024
EBITDA margin
1.0%
-67% vs 2024
Equity ratio
13.3%
Financial strength
Net profit 2025
NOK -7K
-122% vs 2024
| Revenue | NOK 7,6M | -3% |
| EBITDA | NOK 73K | -67% |
| Net profit | NOK -7K | -122% |
| Total assets | NOK 1,3M | -20% |
| Equity | NOK 170K | -4% |
| Employees | 7 | — |
Legal name
BERGEN ØRE-NESE-HALS AS
Org number
919434007
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
22. august 2017
Share capital
NOK 30 000
Employees
7 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styret i fellesskap.
Company purpose
Spesialisert legevirksomhet.
Address
Christian Michelsens Gate 4, 5012 Bergen
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 7 670 | 7 162 | 7 587 | 7 817 | 7 560 |
| Staff expenses | −3 661 | −4 348 | −4 228 | −4 432 | −4 294 |
| EBITDA | 1 133 | −165 | 195 | 222 | 73 |
| Depreciation & amort. | −330 | −341 | −185 | −180 | −81 |
| EBIT | 803 | −506 | 9 | 41 | −8 |
| Net financials | −1 | −1 | 3 | −0 | −0 |
| Profit before tax | 802 | −507 | 12 | 41 | −8 |
| Tax | 177 | −111 | 2 | 9 | −1 |
| Net profit | 626 | −395 | 10 | 32 | −7 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 823 | 2 224 | 1 783 | 1 599 | 1 275 |
| Equity | 530 | 135 | 145 | 177 | 170 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 293 | 2 090 | 1 638 | 1 422 | 1 105 |
| Total debt | 2 293 | 2 090 | 1 638 | 1 422 | 1 105 |
EBITDA margin
1.0%
This company
15.8%
Market median
-94% vs market
20212025
Equity ratio
13.3%
This company
38.2%
Market median
-65% vs market
20212025
Return on equity
-4.1%
This company
18.4%
Market median
-122% vs market
20212025
Net profit margin
-0.1%
This company
8.1%
Market median
-101% vs market
20212025
Asset turnover
5.93×
This company
1.12×
Market median
+429% vs market
20212025
Debt / equity
6.49×
This company
0.62×
Market median
-947% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
HR Chief Executive Officer | Chief Executive Officer | 2017 |
HV Chief Executive Officer | Chief Executive Officer | 2017 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2017 | |
| Chairman | 2017 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 33.33% | 33.33% | 2024 | |
| Company | 33.33% | 33.33% | 2024 | |
| Company | 33.33% | 33.33% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Allergi Og Øre- Nese- Hals As
BERGEN ØRE-NESE-HALS AS Board members of BERGEN ØRE-NESE-HALS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hogne Ravndal Vaagland | Chief Executive Officer | 0 companies |
| Hogne Vaagland | Chief Executive Officer | 0 companies |
| Svein Jacob Tjoflaat Nygaard | Board of Directors | 0 companies |
| Jens-Christian Haug Eriksson | Chairman | 0 companies |